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Effects of vitamin D compounds on renal and intestinal Ca2+
transport proteins in 25-hydroxyvitamin D3-1a-hydroxylase
knockout mice.
Background. Vitamin D compounds are used clinically to
control secondary hyperparathyroidism (SHPT) due to renal
failure. Newer vitamin D compounds retain the suppressive
action of 1,25(OH)2D3 on the parathyroid glands and may
have less Ca2+-mobilizing activity, offering potentially safer
therapies.
Methods. This study investigated the effect of a single dose
of compound (1,25(OH)2D3, 1,24(OH)2D2, or 1a(OH)D2) on
renal and intestinal Ca2+ transport proteins, including TRPV5
and TRPV6, and serum Ca2+, in a novel SHPT model, the 25-
OH-D3-1a-hydroxylase knockout mouse, which lacks endoge-
nous 1,25(OH)2D3 and is severely hypocalcemic. Animals were
injected intraperitoneally with compound (100 ng/mouse).
Results. Serum levels of 1,25(OH)2D3 and 1,24(OH)2D2
peaked at four hours post-injection (pi), then declined
rapidly. 1,25(OH)2D2 generated from 1a(OH)D2 peaked at
12 hours pi and then remained stable. Serum Ca2+ was in-
creased to near-normal within four hours by 1,25(OH)2D3 and
1,24(OH)2D2, and within 12 hours by 1a(OH)D2. 1,25(OH)2D3
and 1,24(OH)2D2 up-regulated duodenal TRPV5 and TRPV6
mRNA to a similar degree within four hours; mRNA levels
decreased by 12 hours after 1,24(OH)2D2 treatment, and by
24 hours after 1,25(OH)2D3 treatment. 1,25(OH)2D3 increased
kidney levels of TRPV5, calbindin-D28K, and calbindin-D9K
mRNA within four hours; 1,24(OH)2D2 did not change kid-
ney TRPV5 levels and modestly increased calbindin D9K by
48 hours. 1a(OH)D2 produced later-onset effects, increasing
duodenal TRPV6 and calbindin-D9K mRNA levels by 12 hours
and TRPV5 by 48 hours.
Conclusion. In kidney, 1a(OH)D2 increased TRPV5,
calbindin-D28K, and calbindin-D9K mRNA levels by 12 hours.
1See Editorial by Goodman, p. 1286.
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This study indicates that Ca2+ transport proteins, including
TRPV5 and TRPV6, are differentially up-regulated by vitamin
D compounds.
Secondary hyperparathyroidism (SHPT), a common
disorder in patients with chronic renal failure, develops
in response to low serum levels of Ca2+ and active vita-
min D metabolites. Vitamin D is a major regulator of Ca2+
homeostasis, and is essential for proper development and
maintenance of bone [1, 2]. The active form of vitamin
D, 1a,25-dihydroxyvitamin D3 (1,25(OH)2D3) is synthe-
sized from its precursor 25-hydroxyvitamin D3 by the
renal cytochrome P450 enzyme 25-hydroxyvitamin D3-
1a-hydroxylase (1a-OHase, CYP27B1). The importance
of this enzyme is underlined by the severe disor-
ders in Ca2+ homeostasis caused by mutations in the
1a-hydroxylase gene, including vitamin D–dependent
rickets type I (VDDR-I) [3]. Low serum levels of
1,25(OH)2D3 resulting from reduced 1a-hydroxylase ac-
tivity in kidneys of renal patients play a major role in the
initiation and maintenance of SHPT [4, 5].
SHPT complicating chronic kidney disease requires
treatment to minimize the effect of elevated parathyroid
hormone (PTH) on bone and other tissues [6]. Vitamin
D compounds have been widely used in the treatment
of this disorder [4, 5, 7–12]. However, use of compounds
such as 1,25(OH)2D3 has frequently been accompanied
by the undesired side effects of hypercalcemia and hyper-
phosphatemia, which increase the risk of soft tissue and
vascular calcification [13]. To avoid these side effects, vi-
tamin D analogs have been developed with the aim of
suppressing PTH secretion with minimal calcemic action
[7–12, 14–16].
Active vitamin D compounds directly increase intesti-
nal and renal Ca2+ (re)absorption through up-regulation
of Ca2+ transport proteins [17–20]. In the mammalian
genome, a distinct family of epithelial Ca2+ channels
(TRPV5 and TRPV6) was recently identified, which
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provides the molecular identity of the apical entry mech-
anism facilitating this active Ca2+ (re)absorption process
[21, 22]. Ca2+ entry via these novel Ca2+ channels is
followed by cytosolic diffusion facilitated by Ca2+ bind-
ing proteins (calbindin-D28K and/or calbindin-D9k) and
active extrusion of Ca2+ across the basolateral mem-
brane by a high-affinity plasma membrane Ca2+-ATPase
(PMCA1b) and a Na+-Ca2+ exchanger (NCX1) [23]. In
this active process, TRPV5 and TRPV6 probably form
the final regulatory target for hormonal control [23], sug-
gesting that these channels could be the primary targets
in the regulation of the Ca2+ reabsorption.
To date, hundreds of vitamin D analogs have been
synthesized, and many investigated for biological ef-
ficacy [24]. The aim of the present study was to
investigate the acute effects of a single dose of vi-
tamin D compounds on Ca2+ transport proteins and
serum Ca2+ in 25-hydroxyvitamin D3-1a-hydroxylase
(1a-OHase) knockout mice [25], a useful animal model
for SHPT with undetectably low serum levels of
1,25(OH)2D3. Animals were dosed with 100 ng of ei-
ther 1,25(OH)2D3, 1a-hydroxyvitamin D2 (1a(OH)D2),
or 1a,24(S)-dihydroxyvitamin D2 (1,24(OH)2D2). Ani-
mals were examined for effects on serum Ca2+ and vita-
min D metabolite levels, and on levels of Ca2+ transport
proteins in kidney and small intestine.
METHODS
Animal protocol
25-hydroxyvitamin D3-1a-hydroxylase (1a-OHase−/−)
knockout mice were recently generated by targeted abla-
tion of exon 8 encoding the heme-binding domain of the
enzyme [25]. 1a-OHase knockout mice were genotyped
by Southern blot in combination with polymerase chain
reaction (PCR) analysis at an age of 3 weeks directly
after the weaning period, as described previously [17,
25]. Homozygous 1a-OHase (1a-OHase−/−) knockout
mice were fed a regular diet containing 1.1% (w/w)
Ca2+, 0.8% (w/w) phosphorus, 0% (w/w) lactose (Harlan
Teklad; Madison, WI, USA) from week three to eight.
At week eight, 1a-OHase−/− mice were injected in-
traperitoneally (ip) with 1,25(OH)2D3, 1,24(OH)2D2, or
1a(OH)D2 (100 ng/mouse). At 4, 12, 24, 48, and 96 hours’
post-injection (pi), mice (N = 3 to 5 in each group) were
sacrificed and blood, kidney, and duodenum samples
were taken, which were subsequently analyzed for Ca2+
and 1,25(OH)2D serum concentrations and expression
of the Ca2+ transporters. The animal ethics board of
the University Medical Center Nijmegen (Nijmegen)
approved all animal experimental procedures.
Serum biochemistry
Serum Ca2+ concentrations were analyzed using a col-
orimetric assay kit as described previously [26]. Circu-
lating levels of active metabolites were determined by
total dihydroxyvitamin D analysis (Nichols Institute Di-
agnostics Kit, cat no. 40–6090; San Juan Capistrano, CA,
USA) as follows: samples of mouse serum (0.1 mL) were
delipidated, and the dihydroxyvitamin D fraction was
separated from potential cross-reactants by incubation
with a highly specific solid-phase monoclonal antibody.
The immunoextraction gel was then washed, and the pu-
rified dihydroxyvitamin D fraction was eluted directly
into glass assay tubes. Calibrators and reconstituted elu-
ates were incubated overnight with a highly specific poly-
clonal sheep antibody. 125I-1,25-dihydroxyvitamin-D was
added and incubation was continued for two more hours.
Separation of bound and free analytes was achieved
during incubation with antisheep precipitant, followed
by centrifugation, decanting, and counting. Bound ra-
dioactivity is inversely proportional to the concentration
of dihydroxyvitamin-D. Metabolite concentrations were
quantified using a standard curve.
Immunohistochemistry
The renal localization of TRPV5 was assessed by
immunohistochemistry as described previously [27]. In
short, staining of renal cortex sections for TRPV5 was
performed on 7-lm sections of fixated frozen kidney
samples. TRPV5 staining involved immersion of the
kidney sections in boiled citrate target retrieval buffer
(0.01 mol/L sodium citrate and 0.01 mol/L citric acid,
pH 6.0), which was then left to cool for 30 minutes,
and subsequent incubation in 0.3% (v/v) H2O2 in buffer
(0.15 mol/L NaCl, 0.1 mol/L Tris-HCl, pH 7.6) for 30 min-
utes. Sections were incubated for 16 hours at 4◦C with
the affinity-purified guinea pig TRPV5 antibody (1:1000)
and TRPV5 protein was detected as described previously
[17, 27]. Images were made using a Nikon Diaphot confo-
cal laser scanning microscope (Tokyo, Japan; MRC-1000;
Bio-Rad, Richmond, CA, USA) and a Zeiss fluorescence
microscope equipped with a digital photo camera (Nikon
DMX1200). For semiquantitative determination of pro-
tein levels, digital images were analyzed with the Image
Pro Plus 4.1 image analysis software (Media Cybernet-
ics; Silver Spring, MD, USA), resulting in quantification
of the protein levels as the mean of integrated optical
density (IOD).
Real-time PCR analysis
Total RNA was extracted from kidney and duodenum
using TriZol Total RNA Isolation Reagent (Gibco BRL;
Breda, The Netherlands). The obtained RNA was sub-
jected to DNAse treatment to prevent genomic DNA
contamination. Thereafter, 2 lg RNA was reverse tran-
scribed by Moloney-Murine Leukemia Virus-Reverse
Transcriptase (M-MLV-RT; Gibco BRL), as described
previously [17]. The obtained renal cDNA was used to
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determine TRPV5, calbindin-D9K, calbindin-D28K, Na+-
Ca2+ exchanger (NCX1), and plasma membrane ATPase
(PMCA1b) mRNA expression levels, as well as mRNA
levels of the housekeeping gene hypoxanthine-guanine
phosphoribosyl transferase (HPRT) as an endoge-
nous control. The cDNA transcribed from duodenum
RNA was assayed for TRPV5, TRPV6, calbindin-D9K,
PMCA1b, and HPRT mRNA expression levels. Poly-
merase chain reaction (PCR) primers and fluorescent
probes were designed using the computer program
Primer Express (Applied Biosystems, Foster City, CA,
USA) and purchased from Biolegio (Malden, The
Netherlands). The primer and probe sequences for
TRPV5, TRPV6, calbindin-D9K, calbindin-D28K, NCX1,
PMCA1b, and HPRT were described previously [17]. Ex-
pression levels were quantified by real-time quantitative
PCR on an ABI Prism 7700 Sequence Detection System
(PE Biosystems, Rotkreuz, Switzerland).
Statistical analysis
The serum Ca2+ and vitamin D metabolite concentra-
tions were expressed as the mean ± SEM. Overall statis-
tical significance was determined by analysis of variance
(ANOVA). In the case of significance (P < 0.05), individ-
ual groups were compared by contrast analysis according
to Fisher.
RESULTS
Serum Ca2+ and vitamin D metabolites
Initially, a dose response analysis was carried out
in 8-week-old 1a-OHase−/− mice using 50, 100, and
150 ng/animal of either 1,25(OH)2D3, 1,24(OH)2D2, or
1a(OH)D2. Maximal responses on the expression of the
Ca2+ transport genes were observed at 100 ng (data
not shown), and this dose was chosen for further in-
vestigation. Subsequently, the effects of 1,25(OH)2D3,
1a(OH)D2, and 1,24(OH)2D2 administration on serum
Ca2+ and vitamin D metabolite levels in 1a-OHase−/−
mice at time points from four to 96 hours were de-
termined (Fig. 1). Control 1a-OHase−/− mice treated
with vehicle exhibited severe hypocalcemia with serum
Ca2+ concentrations around 1.5 mmol/L (Fig. 1A). In-
traperitoneal administration of a single 100 ng dose
of 1,25(OH)2D3 or 1,24(OH)2D2 significantly increased
serum Ca2+ concentration to near-normal values of
around 2 mmol/L within four hours (Fig. 1A). The
serum Ca2+ concentrations remained increased up to
96 hours pi, declining slightly in the case of 1,24(OH)2D2.
In contrast, serum Ca2+ was not increased by 1a(OH)D2
until 12 hours. This compound, a prodrug, requires sys-
temic metabolism to active metabolites to exert effects.
Serum Ca2+ levels were increased by 1a(OH)D2 over
the remaining time points examined (Fig. 1A), but never
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Fig. 1. Serum Ca2+ (A) and 1a,25(OH)2D (B) concentrations
in 1a-OHase−/− mice supplemented with 1a,25(OH)2D3 (black),
1a(OH)D2 (diagonal stripes) or 1a,24(S)(OH)2D2 (white) at differ-
ent time points in hour. Data are mean ± SEM (N = 3 to 5). ∗P < 0.05,
significantly different from 1a-OHase−/− treated with vehicle only.
exceeded the serum Ca2+ levels of normal littermates
(2.5 mmol/L).
Analysis of vitamin D metabolite levels following dose
administration showed that 1,25(OH)2D3 produced a sig-
nificant increase in serum 1,25(OH)2D concentrations
that peaked at four hours pi and subsequently declined
gradually (Fig. 1B). Serum levels of 1,24(OH)2D2 fol-
lowed a time course similar to 1,25(OH)2D3, but were
consistently about 25% of 1,25(OH)2D3 levels. Adminis-
tration of 1a(OH)D2 produced 1,25(OH)2D serum levels
that reached approximately 600 pg/mL at 12 hours pi, and
then remained relatively constant for the remaining time
points (Fig. 1B).
Expression of Ca2+ transport genes in kidney
The effect of 1,25(OH)2D3, 1a(OH)D2, and
1,24(OH)2D2 on mRNA levels of Ca2+ transport
genes (TRPV5, calbindin-D9K, calbindin-D28K, NCX1,
and PMCA1b) in the kidney was investigated using
total RNA isolated from kidney cortex and real-time
quantitative PCR (Fig. 2). 1,25(OH)2D3 supplemen-
tation produced a 2.5-fold increase in TRPV5 mRNA
expression at four hours pi compared to vehicle-treated
mice (Fig. 2A). Expression of TRPV5 was significantly
increased from four hours’ pi onwards. Significant
up-regulation of calbindin-D28K (1.5- to 2-fold) and
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Fig. 2. The effect of 1a,25(OH)2D3 (black), 1a(OH)D2 (diagonal
stripes), and 1a,24(S)(OH)2D2 (white) on the expression of the re-
nal Ca2+ transport genes, including TRPV5 (A), calbindin-D28K (B),
calbindin-D9K (C), NCX1 (D), and PMCA1b (E) in 1a-OHase−/−
mice assessed by real-time polymerase chain reaction (PCR) analysis.
Values are calculated as a ratio to the hypoxanthine-guanine phospho-
ribosyl transferase (HPRT) RNA level and expressed relative to levels
of 1a-OHase−/− mice treated with vehicle. Values are presented as
mean ± SEM (N = 3 to 5). ∗P < 0.05, significant different from 1a-
OHase−/− treated with vehicle only (control).
calbindin-D9K (2- to 12-fold) mRNA was also produced
by 1,25(OH)2D3 (Fig. 2B and C). NCX1 mRNA ex-
pression was not significantly affected by 1,25(OH)2D3
(Fig. 2D), whereas a slight reduction was observed for
PMCA1b (Fig. 2E).
Administration of 1,24(OH)2D2 did not significantly
affect mRNA expression levels of TRPV5 and calbindin-
D28K (Fig. 2A and B). Remarkably, calbindin-D9K and
NCX1 mRNA were up-regulated at the late time points,
48 and 96 hours pi, whereas PMCA1b mRNA was slightly
decreased (Fig. 2C to E).
Administration of 1a(OH)D2 increased mRNA ex-
pression of TRPV5, calbindin-D28K, and calbindin-D9K in
the kidney. Although the degree of mRNA up-regulation
induced by 1a(OH)D2 was comparable to those of
1,25(OH)2D3, there was a slight delay in the response to
1a(OH)D2 (Fig. 2A to C). Expression of the basolateral
extrusion genes (NCX1 and PMCA1b) was not robustly
affected by 1a(OH)D2 (Fig. 2D and E).
Analysis of TRPV5 protein levels in kidney
TRPV5 protein expression in the kidney was ex-
amined using immunohistochemistry. Fig. 3A shows
representative immunofluorescence labeling of distal
convoluted (DCT) and connecting tubules (CNT) in
sections of kidney cortex from 1a-OHase knockout
mice supplemented with 1,25(OH)2D3, 1a(OH)D2, or
1,24(OH)2D2. More TRPV5 protein was detected at
96 hours pi in the 1,25(OH)2D3- and 1a(OH)D2-
supplemented mice, indicated by the increased staining
in the kidney cortex. In these immunopositive tubules,
TRPV5 was localized to the apical membrane of DCT
and CNT. To semiquantify TRPV5 protein expression,
the IOD was measured with computer analysis using the
Image-Pro Plus software version 3.0 (Fig. 3B). In line with
the observed TRPV5 expression at the mRNA level, the
response on protein expression for 1a(OH)D2 was de-
layed (48 hours) compared to 1,25(OH)2D3 (12 hours).
For 1,24(OH)2D2, a significant increase in TRPV5 ex-
pression was observed only at 96 hours pi (Fig. 3B).
Expression of Ca2+ transport genes in duodenum
Subsequently, we investigated whether treatment with
these vitamin D compounds altered the expression of
genes encoding Ca2+ transport proteins involved in duo-
denal transcellular Ca2+ absorption. Administration of
1,25(OH)2D3 produced a >30-fold increase in TRPV6
mRNA levels by four hours’ pi (Fig. 4B). In line with
these findings, TRPV5 and calbindin-D9K were also sig-
nificantly up-regulated (Fig. 4A, C). Levels of TRPV5
and TRPV6 mRNA remained elevated at 12 hours pi, re-
turning to baseline by 24 hours pi; calbindin-D9K mRNA
remained elevated out to 96 hours pi. PMCA1b mRNA
expression was slightly, but significantly, increased at
1086 Hoenderop et al: Rescue of 1a-hydroxylase knockout mice by vitamin D compounds
A
1α,24(S)(OH)2D2
1α,25(OH)2D3
1α(OH)D2 1α(OH)D2500
400
300
200
100
0
Crtl 4 12 24 48 96 hours
*
*
IO
D 
×
 1
03
,
ar
bi
tra
ry
 u
ni
ts
1α,25(OH)2D3200
150
100
50
0
IO
D 
×
 1
03
,
ar
bi
tra
ry
 u
ni
ts
Crtl 4 12 24 48 96 hours
*
*
*
*
B 1α,24(S)(OH)2D3           200
150
100
50
0
IO
D 
×
 1
03
,
ar
bi
tra
ry
 u
ni
ts
Ctrl 4 12 24 48 96 hours
*
Fig. 3. The effect of 1a,25(OH)2D3,
1a(OH)D2, or 1a,24(S)(OH)2D2 on renal
TRPV5 protein expression in 1a-OHase−/−
mice. Representative immunohistochemistry
of TRPV5 in the kidney cortex at 4 and 96
hours post-administration (A). Averaged
TRPV5 protein expression levels were
calculated by measuring the integral optical
density (IOD) using the Image-Pro Plus
version 3.0 software (B). Values are presented
as mean ± SEM (N = 3 to 5). ∗P < 0.05,
significantly different from 1a-OHase−/−
treated with vehicle only (control).
48 to 96 hours post-administration of 1,25(OH)2D3
(Fig. 4D).
1,24(OH)2D2 -treatment resulted in a rapid 24-fold
up-regulation of TRPV6 mRNA in duodenum by four
hours pi (Fig. 4B). TRPV5 and calbindin D9K mRNA
were also significantly increased (Fig. 4A and C). This
rapid increase in TRPV5 and TRPV6 mRNA expression
was transient and returned quickly to control values at
12 to 96 hours pi. Calbindin-D9K mRNA expression re-
mained elevated during the entire studied time interval.
No significant change was observed in the level of mRNA
encoding PMCA1b (Fig. 4D).
Supplementation with 1a(OH)D2 resulted in a de-
layed, but significant up-regulation of TRPV6 (160-fold)
and TRPV5 (8-fold) mRNA that was maximal at 96 hours
post-administration (Fig. 4A and B). In addition, up-
regulation of both Ca2+ channels was accompanied by
an increase in expression of calbindin-D9K (3- to 15-fold)
(Fig. 4C). In contrast, PMCA1b expression was elevated
only at 96 hours pi (Fig. 4D).
DISCUSSION
Vitamin D compounds including 1,25(OH)2D3 are
widely used in the treatment of SHPT because of their
efficacy in reducing elevated PTH levels. High PTH lev-
els are deleterious to the skeleton, particularly to cortical
bone [28], and may have pathologic effects on other tis-
sues as well [6]. Normalization of PTH levels and bone
histology were observed in patients with renal failure
who were treated with vitamin D compounds includ-
ing 1a(OH)D3 and 1,25(OH)2D3 [29, 30]. However, hy-
percalcemia develops frequently in patients treated with
older compounds, such as 1,25(OH)2D3, limiting their
clinical application [31]. Thus, novel vitamin D com-
pounds, with efficacy in PTH reduction and reduced ef-
fects on systemic Ca2+, have been developed with the goal
of minimizing this unwanted side effect [7–12, 14–16].
Several experimental animal models have been uti-
lized to study Ca2+ transport proteins and their
disturbances linked to parathyroid activity. Recently, 1a-
OHase knockout mice strains have been generated that
represent a valuable animal model for pseudovitamin D
deficiency rickets (PDDR) and SHPT [25, 32]. Untreated
1a-OHase−/− mice presented the same clinical pheno-
type as patients with PDDR, including markedly elevated
serum PTH levels, retarded growth, failure to thrive, se-
vere hypocalcemia, bone abnormalities (including rickets
and osteomalacia), and undetectably low serum levels of
1,25(OH)2D3. The last feature was particularly impor-
tant because our goal was to quantitate the effects of vi-
tamin D compounds on Ca2+ transport proteins. Because
the transgenic mice completely lacked background levels
of 1,25(OH)2D3, the immediate effects of exogenously
administered vitamin D compounds could be assigned
unambiguously. In the absence of renal 1a-OHase activ-
ity, no feedback inhibition of endogenous 1,25(OH)2D3
synthesis by exogenous compounds was possible, sim-
plifying analysis at later time points. Furthermore, the
transgenic animals are a robust model, reliably develop-
ing the PDDR phenotype. Models employed in the past
to produce low serum levels of 1,25(OH)2D3, such as the
vitamin D–deficient rat, require subjecting experimental
animals to a vitamin D–deficient diet under ultraviolet
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Fig. 4. The effect of 1a,25(OH)2D3 (black), 1a(OH)D2 (diagonal
stripes), and 1a,24(S)(OH)2D2 (white) on the expression of the duode-
nal Ca2+ transport genes, including TRPV5 (A), TRPV6 (B), calbindin-
D9K (C), and PMCA1b (D) in 1a-OHase−/− mice assessed by real-time
polymerase chain reaction (PCR) analysis. Values are calculated as a
ratio to the hypoxanthine-guanine phosphoribosyl transferase (HPRT)
RNA level and expressed relative to levels of 1a-OHase−/− mice
treated with vehicle. Values are presented as mean ± SEM (N = 3
to 5). ∗P < 0.05, significantly different from 1a-OHase−/− treated with
vehicle only (control).
(UV)-free conditions for months, and in our experience,
often meet with limited success in producing the desired
phenotype. For the above reasons, these transgenic mice
offer an ideal model in which to study the activity of vita-
min D compounds on serum Ca2+ and the expression of
Ca2+ transport genes. Recent work from our laboratory
indicates that the renal Ca2+ transport proteins, including
TRPV5, calbindin-D9K, calbindin-D28K, and NCX1 are
down-regulated in kidneys of 1a-OHase−/− mice [17, 19].
Furthermore, mRNA encoding TRPV6, calbindin-D9K,
and PMCA1b is decreased in duodenum [19]. Treatment
with 1,25(OH)2D3 normalizes serum Ca2+ levels and the
expression of the Ca2+ transport proteins in these knock-
out animals [17].
In the present study, we examined the effect of three vi-
tamin D compounds, namely 1,25(OH)2D3, 1a(OH)D2,
and 1,24(OH)2D2 on serum Ca2+ and vitamin D lev-
els, and on the expression of Ca2+ transport genes in
the kidney and duodenum in 1a-OHase knockout mice.
1,25(OH)2D3 has been used previously in many studies
of Ca2+ transport proteins and was included as the proto-
typic active vitamin D compound. 1a(OH)D2 is a vitamin
D prodrug, less calcemic than 1,25(OH)2D3 in animal
studies [6], which must be metabolized to become active,
resulting in altered pharmacokinetics relative to active
vitamin D compounds. 1a(OH)D2 has recently been ap-
proved in the United States for the treatment of SHPT
of renal failure. 1,24(OH)2D2 is an active metabolite of
1a(OH)D2 with greatly reduced calcemic activity relative
to 1,25(OH)2D3 [33, 35].
All three compounds, administered as a single in-
traperitoneal dose of 100 ng, were able to increase serum
Ca2+ levels toward the normal range in knockout mice.
1,25(OH)2D3 and 1,24(OH)2D2 increased serum Ca2+
from 1.5 to 2 mmol/L within four hours pi (Fig. 1A),
while 1a(OH)D2 increased serum Ca2+ to 2 mmol/L
by 12 hours pi. These increases in serum Ca2+ cor-
related well with the pharmacokinetics of the vitamin
D compounds. Serum levels of both 1,24(OH)2D2 and
1,25(OH)2D3 increased rapidly after dose administra-
tion, reaching a peak at four hours pi, and then decreasing
rapidly. This spike in serum levels of 1,24(OH)2D2 and
1,25(OH)2D3 resembled that seen in wild-type animals
[33]. In contrast, serum levels of 1a,25(OH)2D2 produced
from 1a(OH)D2 reached a peak at 12 hours pi, which re-
flects the delayed hepatic activation of this prodrug.
The additional time required to increase serum
1a,25(OH)2D2 levels following 1a(OH)D2 administra-
tion, relative to active compounds, correlated well with
the additional time required by 1a(OH)D2 to increase
serum Ca2+. Unexpectedly, however, serum levels of
1a,25(OH)2D2 produced from 1a(OH)D2 remained el-
evated out to 96 hours postdose, a significant depar-
ture from the pharmacokinetics observed previously
for 1a(OH)D2, in which serum levels of 1,25(OH)2D2
returned to baseline by 48 hours postdose [34]. The
continued elevation of serum 1a,25(OH)2D2 in 1a-
OHase−/− animals 96 hours after a single dose of
1a(OH)D2 may result from low initial levels of CYP24
[25], the major catabolic enzyme for vitamin D com-
pounds, combined with the very large dose of 1a(OH)D2
used in this study.
Interestingly, like serum Ca2+ levels, TRPV5 and
TRPV6 mRNA levels in duodenum increased in par-
allel with serum levels of vitamin D compounds.
Both 1,25(OH)2D3 and 1,24(OH)2D2 induced a rapid
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increase in duodenal TRPV5 and TRPV6 levels (35-fold
and 20-fold, respectively, for TRPV6) within four hours,
while 1a(OH)D2 did not up-regulate TRPV6 levels until
12 hours pi. The effect of 1a(OH)D2 on TRPV5 mRNA
in duodenum was also later onset, with no increase at
early time points, and then pronounced up-regulation.
Effects of vitamin D compounds on Ca2+ regula-
tory genes in kidney were more diverse. Interestingly,
1,24(OH)2D2 did not up-regulate TRPV5 or calbindin
mRNA in kidney at any time point. In contrast,
1,25(OH)2D3 significantly increased both TRPV5 and
calbindin mRNA levels by four hours pi. 1a(OH)D2 sig-
nificantly increased mRNA levels of TRPV5 and cal-
bindin at 12 hours pi and later. Both 1,25(OH)2D3 and
1a(OH)D2 up-regulated mRNA levels of the Ca2+ trans-
port genes in the kidney to a similar degree. TRPV5
protein expression was up-regulated by 1a(OH)D2 exclu-
sively along the apical side of tubules in the distal part of
the nephron, in agreement with previous studies [18]. In
general, increases in expression of Ca2+ transport genes
by vitamin D compounds were smaller in kidney than in
duodenum, but still significant.
An intriguing aspect of the present study was that
1,25(OH)2D3, and to a lesser extent 1,24(OH)2D2, ap-
peared to have a biphasic effect on mRNA levels of
TRPV5 levels in kidney and duodenum, and TRPV6 lev-
els in duodenum; mRNA levels were highly increased by
four to 12 hours, declined at 24 hours, then increased again
by 96 hours (Figs. 2A, 3B, and 4A). Levels of TRPV5 and
TRPV6 mRNA in duodenum, and TRPV5 protein in kid-
ney, were also highly induced at later time points (48 and
96 hours) by 1a(OH)D2. The reason for this biphasic or
later onset effect is unclear, and further studies will be
necessary to determine the underlying mechanism.
The effects of 1a(OH)D2 on mRNA levels of Ca2+
transport proteins were more pronounced at later time
points in both duodenum and kidney. The sustained
supraphysiologic levels of 1,25(OH)2D2 (approximately
600 pg/mL) at 12 to 96 hours pi following the large dose
of 1a(OH)D2 (approximately 5 lg/kg) produced strong
induction of Ca2+ transport proteins at later time points
in both duodenum and kidney (Figs. 3B, 4A to D), which
may account for the continued gradual increase in serum
Ca2+ produced by 1a(OH)D2. Of note, even at the large
dose used, the levels of serum Ca2+ in transgenic mice
treated with 1a(OH)D2 never exceeded those of normal
littermates (2.5 mmol/L).
The data in the present study may shed light on the
mechanism underlying the reduced calcemic activity of
1,24(OH)2D2. As noted, 1,24(OH)2D2 is a metabolite
of vitamin D2 and 1a(OH)D2, which is 10- to 30-fold
less calcemic than 1,25(OH)2D3 [33]. As in normal
animals [33], 1,24(OH)2D2 serum levels in knockout
animals were consistently about 25% of 1,25(OH)2D3
levels. Despite this, 1,24(OH)2D2 increased serum Ca2+
to the same extent as 1,25(OH)2D3 at four hours pi, and
increased duodenal levels of TRPV5 and TRPV6 levels
to the same degree (Fig. 4A and B). The equivalent abil-
ity of 1,24(OH)2D2 and 1,25(OH)2D3 to increase serum
Ca2+ levels in this study may have resulted from the large
dose of compound used, which was deliberately chosen
to maximize the responses of Ca2+ transporter genes in
the knockout animals. However, even at this large dose,
animals treated with 1,24(OH)2D2 showed a rapid de-
cline in TRPV5 and TRPV6 mRNA levels in duodenum
after initial induction, returning to near baseline levels
at 12 hours pi; in animals treated with 1,25(OH)2D3,
TRPV5 and TRPV6 levels remained elevated or even
increased further at 12 hours pi (Fig. 4A and B). As
noted, 1,24(OH)2D2 did not increase kidney levels of
TRPV5 or calbindin-D28K at any time point. Taken to-
gether, the data suggest that the reduced calcemic effects
of 1,24(OH)2D2 may result from a reduced effect on Ca2+
channel proteins in target organs, through either reduced
magnitude of induction or reduced duration of induc-
tion. Further studies will be necessary to confirm this
hypothesis.
CONCLUSION
This study provides evidence that TRPV5 and TRPV6
are differentially up-regulated by vitamin D analogs. The
time course of up-regulation of these epithelial Ca2+
transporters appears to correlate well with serum lev-
els of active vitamin D metabolites. 1a(OH)D2 provided
normalization of serum Ca2+ and up-regulation of the
epithelial Ca2+ transporters that was maintained for an
extended period, whereas at the same dose 1,24(OH)2D2
and 1,25(OH)2D3 produced a more rapid increase in
serum Ca2+ concentration. Further studies are under way
to define the roles of TRPV5 and TRPV6 in vitamin
D–regulated Ca2+ transport and to determine the rela-
tive contribution of these epithelial Ca2+ transporters to
vitamin D–mediated Ca2+ homeostasis.
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